Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.

Merck MRK is going to face a major patent cliff, as its blockbuster PD-L1 therapy Keytruda is nearing loss of exclusivity (LOE) in 2028. The company’s biggest revenue driver, Keytruda, is approved for ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

The Munich Regional Court ruled there was imminent infringement for Merck & Co.’s Keytruda SC in Germany related to ...

In a setback for Merck, a German court issued a preliminary injunction that prevents the company from distributing a new ...

The company is finding ways to overcome the headwinds it will encounter in the medium term.

After a long hiatus, why are the bulls so willing to buy in now?

Merck demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar capital allocation. Learn more about MRK stock here.

The rebound is well underway.

A German court has ordered Merck & Co (NYSE: MRK) to halt launch preparations for its new subcutaneous version of Keytruda ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted the company’s strategic planning for when Keytruda loses patent protection.

The Food and Drug Administration approved Merck's Keytruda in combination with Padcev to treat certain adults with muscle invasive bladder cancer (MIBC). The FDA said Friday it has approved the drug ...